Modified Measles Virus + Modified Measles Virus Lumbar Puncture
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Medulloblastoma, Childhood, Recurrent
Conditions
Medulloblastoma, Childhood, Recurrent, Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma Recurrent
Trial Timeline
Feb 22, 2017 → May 10, 2023
NCT ID
NCT02962167About Modified Measles Virus + Modified Measles Virus Lumbar Puncture
Modified Measles Virus + Modified Measles Virus Lumbar Puncture is a phase 1 stage product being developed by Brain Biotech for Medulloblastoma, Childhood, Recurrent. The current trial status is completed. This product is registered under clinical trial identifier NCT02962167. Target conditions include Medulloblastoma, Childhood, Recurrent, Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma Recurrent.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02962167 | Phase 1 | Completed |
Competing Products
9 competing products in Medulloblastoma, Childhood, Recurrent
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2940680 + LY2940680 | Eli Lilly | Phase 1 | 33 |
| LDE225 + TMZ | Novartis | Phase 2 | 52 |
| LDE225 | Novartis | Phase 1/2 | 41 |
| Lomustine + Vincristine + Cisplatin + Cyclophosphamide + Mesna + Vincristine | Brain Biotech | Phase 1 | 25 |
| CX 4945 | Brain Biotech | Phase 1/2 | 33 |
| SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years + SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years + SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years | Brain Biotech | Phase 1 | 25 |
| PEP-CMV | Brain Biotech | Phase 1 | 25 |
| Apatinib Combined With Temozolomide and Etoposide Capsules | Brain Biotech | Phase 2 | 44 |
| Irinotecan + Temozolomide + Bevacizumab + Omburtamab I-131 + Liothyronine + SSKI + Dexamethasone + Antipyretic + Antihistamine + anti-emetics | Brain Biotech | Phase 2 | 44 |